
Editor's Note: Platinum-based chemotherapy combined with immunotherapy has become an important perioperative treatment option for resectable non-small cell lung cancer (NSCLC). However, selecting an appropriate regimen remains challenging for patients who are unsuitable for platinum-based chemotherapy. At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Xue Meng's team presented a phase II exploratory study investigating stereotactic body radiotherapy (SBRT) followed sequentially by iparomlimab/toviralimab (hereinafter referred to as the “Ipa-Tori combination antibody”), with continued immunotherapy after surgery. In the first-stage results, all nine patients achieved a major pathological response (MPR), representing an MPR rate of 100%. The pathological complete response (pCR) rate was 55.6% (5/9), and all patients underwent R0 resection. These findings provide preliminary support for further investigation, although validation in a larger patient population is needed. Oncology Frontier interviewed Professor Xue Meng about the study design, patient selection, and directions for further validation.
100% MPR Rate: Exploring a New Treatment Approach for NSCLC
Oncology Frontier: How should the pathological response results of this study be interpreted? Compared with neoadjuvant chemotherapy combined with immunotherapy, what are the potential clinical value and limitations of this approach?
Professor Xue Meng: This study focuses on patients who are unsuitable for platinum-based chemotherapy but may still be candidates for neoadjuvant treatment and surgery. The study first administered SBRT to the primary tumor, followed sequentially by the Ipa-Tori combination antibody, with adjuvant treatment continued after surgery. Its primary objective was to evaluate the feasibility of this chemotherapy-free neoadjuvant approach.
The study adopted a Simon two-stage design and enrolled patients aged 18–75 years with clinical stage II–IIIB NSCLC, negative for EGFR and ALK alterations, who were considered eligible for surgery following evaluation by the study team. Treatment consisted of SBRT at a total dose of 24 Gy delivered in three fractions on alternate days. Within seven days after radiotherapy, patients began treatment with the Ipa-Tori combination antibody at 5 mg/kg every 21 days for two cycles. Radical surgery was performed 4–8 weeks after completion of neoadjuvant treatment, followed by adjuvant treatment with the Ipa-Tori combination antibody for up to one year.
A total of nine patients were enrolled in the first stage, and all achieved R0 resection. The MPR rate was 100% (9/9), and the pCR rate was 55.6% (5/9). Given the limited sample size and the absence of a control group, it would be inappropriate at this stage to directly compare these pathological response rates with those reported in other studies. Subsequent randomized controlled studies will need to validate the efficacy of this approach and determine whether pathological response is associated with improvements in event-free survival (EFS), disease-free survival (DFS), or overall survival (OS).
Exploring the Potential Beneficiaries of Sequential SBRT and Immunotherapy
Oncology Frontier: What are the innovative aspects of this neoadjuvant radioimmunotherapy approach? Which patients might be more suitable for exploring a chemotherapy-free strategy?
Professor Xue Meng: The study administers SBRT first, followed sequentially by the Ipa-Tori combination antibody, with adjuvant treatment continued after surgery. SBRT may influence subsequent immunotherapy through local tumor control and modulation of the tumor immune microenvironment. However, this mechanism has not yet been directly validated in this study. The Ipa-Tori combination antibody targets both the PD-1 and CTLA-4 pathways. Postoperative administration is also part of the study protocol, and its contribution to long-term benefit remains to be evaluated through follow-up.
This regimen does not include chemotherapy. The study primarily aims to assess the feasibility of sequentially administering SBRT and immunotherapy. Exploratory imaging analyses showed decreases in SUVmax, SUVmean, total lesion glycolysis (TLG), and metabolic tumor volume (MTV) on FDG PET/CT after treatment compared with baseline. Changes in SUVmean in metastatic lymph nodes differed between patients who achieved pCR and those who did not (P=0.043). These findings may provide leads for hypotheses in future research, but they are currently insufficient to support patient selection or guide clinical decision-making.
At present, the study has not established which patient population is most likely to benefit from this regimen. Future investigations could focus on patients without oncogenic driver alterations who are considered eligible for surgery by a multidisciplinary team (MDT), but who are unsuitable for platinum-based chemotherapy because of age, comorbidities, or physical condition. Before enrollment, patients still require comprehensive assessment of pulmonary function, organ function, tumor stage, radiotherapy target safety, contraindications to immunotherapy, and surgical feasibility.
Future studies should document whether surgery is performed as planned, the R0 resection rate, extent of resection, perioperative complications, and postoperative recovery. Long-term follow-up should assess locoregional recurrence, distant metastasis, EFS, DFS, and OS. Pulmonary function, respiratory symptoms, physical recovery, and quality of life should also be incorporated into the evaluation of clinical benefit.
From Single-Arm Exploration to Randomized Controlled Validation: A Promising Path Ahead
Oncology Frontier: Following the release of the first-stage results, how will the study proceed? What insights does this exploration offer for the design of future studies in locally advanced resectable NSCLC?
Professor Xue Meng: All nine patients in the first stage underwent surgery and achieved R0 resection. The median operative time was 172 minutes, and three patients experienced postoperative complications. The abstract did not specify the types or severity of these complications, so the available data are insufficient to fully evaluate perioperative safety at this stage. During neoadjuvant treatment, six patients experienced treatment-related adverse events (66.7%), including two patients with grade 3 adverse events (22.2%). The main events included lymphopenia, anemia, and elevated liver enzymes.
Based on the first-stage results, the study team initiated a randomized controlled phase II cohort, with a planned enrollment of 56 patients. The study compares the chemotherapy-free regimen of sequential SBRT and the Ipa-Tori combination antibody with standard chemotherapy combined with immunotherapy. At the time of this interview, 43 patients had been enrolled, and recruitment was expected to be completed by the end of 2026. In an interim subgroup of patients who had already undergone surgery, the pCR rate was approximately 37% in the radiotherapy-plus-immunotherapy group, compared with less than 30% in the control group. These figures do not represent a complete between-group analysis. Final results will require formal statistical analysis after all patients have completed treatment and follow-up.
Subsequent analyses will also need to clarify the relationship between pathological response and long-term survival outcomes, while systematically evaluating perioperative safety. Radiotherapy dose, fractionation schedule, and the interval between SBRT and immunotherapy should be predefined in the study protocol. PD-L1 expression, ctDNA, PET/CT parameters, and the tumor immune microenvironment may serve as candidate biomarkers, but their value in patient selection still requires prospective validation.
Building the Evidence Base to Guide Future Practice
The clinical significance of this study lies in incorporating local radiotherapy and dual-target immunotherapy into an evaluable perioperative treatment pathway. It also raises an important clinical research question: For patients who are unsuitable for platinum-based chemotherapy but remain eligible for surgery, is it possible to achieve sufficient tumor regression and safely complete surgery without using chemotherapy? The 100% MPR rate and 55.6% pCR rate in the first stage provide encouraging signals for further investigation, and the randomized controlled phase II study is ongoing.
The value of this study extends beyond the pathological response rates themselves. It seeks to address three key questions at progressively deeper levels. First, can patients undergo radical surgery as planned and safely navigate the perioperative period? This is a prerequisite for the feasibility and accessibility of the regimen. Second, can early pathological responses translate into more durable disease control and survival benefits, as measured by EFS, DFS, and OS? This is central to establishing its efficacy. Third, can potential biomarkers, including PD-L1 expression, dynamic changes in ctDNA, and metabolic parameters on FDG PET/CT, be used to predict treatment response and guide patient selection? These possibilities require further validation in subsequent studies.
For chemotherapy-free neoadjuvant approaches, the central clinical concerns involve two aspects: first, accurately identifying the population most likely to benefit from this treatment strategy; and second, ensuring perioperative safety while achieving deep tumor responses. Definitive answers to these questions will depend on the ongoing randomized controlled phase II study and long-term follow-up data.
Professor Xue Meng
